PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 4, 20261 citations

Dosing Interval Extension of Dupilumab in CRSwNP: Five-Year Real World Outcomes.

View Full Paper
NCNicholas J. CampionVienna General HospitalDPDioni-Pinelopi PetsiouVienna General HospitalFFFlorian C FallyVienna General Hospital

Key Points

  • Explore the long-term effects of dupilumab with extended dosing intervals in managing CRSwNP.
  • Evaluated the effects of personalized dosing intervals of dupilumab over five years.
  • Monitored disease control and safety profiles of patients during the treatment.
  • Analyzed changes in treatment burden and side effects associated with any dosing adjustments.
  • Dupilumab therapy provided sustained disease control over five years.
  • Extended dosing intervals maintained efficacy while reducing overall treatment burden.
  • Safety profiles remained excellent throughout the treatment period.

Abstract

Long-term dupilumab therapy provided durable disease control and excellent safety. Personalized dosing-interval extension maintained efficacy and reduced treatment burden, supporting its potential role in optimizing long-term management of CRSwNP, especially in patients with troublesome side effects.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Campion et al. (2026) studied this question.

synapsesocial.com/papers/69a7cd3dd48f933b5eed96e3https://doi.org/10.1002/alr.70125
Ask AI
Helpful
Bookmark
Share
View Full Paper